 |
|
Timing of corticosteroids in non-severe non-hospitalized COVID-19 patients: open-label, two-center, randomized controlled study (TICS-COV19 study)
Emad R. Issak, Mariam M. Amin
Korean J Intern Med. 2023;38(2):207-217. Published online 2023 Jan 17 DOI: https://doi.org/10.3904/kjim.2022.232
|
|
Citations to this article as recorded by
 Efficacy of corticosteroid therapy for oxygen-free coronavirus disease 2019-derived pneumonia
Zentaro Saito, Osamu Kanai, Natsumi Okamoto, Isao Watanabe, Mitsuhiro Tsukino
Medicine.2024; 103(28): e38932. CrossRef Prevalence and Outcomes of Candida auris Infections in a Tertiary Hospital in the United Arab Emirates (UAE)
Ahmad Subhi, Salma Alshamsi, Aulin Vitus, Akram Harazeen
Cureus.2024;[Epub] CrossRef The Efficacy of Oral/Intravenous Corticosteroid Use in COVID-19 Patients: A Systematic Review
Irma Latarissa, Farida Rendrayani, Ghina Iftinan, Cecep Suhandi, Anna Meiliana, Ida Sormin, Melisa Barliana, Keri Lestari
Journal of Experimental Pharmacology.2024; Volume 16: 321. CrossRef Corticosteroids for non-severe COVID-19 infections? Too early to conclude
Sunghoon Park
The Korean Journal of Internal Medicine.2023; 38(2): 144. CrossRef
|